Flumazenil

Benzodiazepines are commonly used clinical sedative-hypnotics. Excessive use or residual sedative effect after anesthesia often leads to central inhibition risks. In response to this clinical demand, the development of specific antidotes has long attracted attention. Flumazenil is a benzodiazepine receptor antagonist. It competitively binds to the benzodiazepine site on the central γ-aminobutyric acid complex and blocks the pharmacological effect of its agonists. It can not only rapidly reverse the toxic symptoms such as drowsiness, coma and respiratory depression caused by excessive benzodiazepine use, but is also commonly used for awakening after anesthesia and differentiating benzodiazepine poisoning from other central nervous system inhibitory diseases. The applicable population includes emergency poisoning patients, surgical patients receiving benzodiazepine anesthesia and related diagnostic populations.

The global flumazenil market size has maintained steady growth in recent years. In 2023, the market size was approximately USD 120 million, with a compound annual growth rate of around 4.7%. The growth drivers mainly come from the increasing demand for emergency poisoning treatment and the popularization of outpatient anesthesia and day surgery. In terms of the domestic market, more than 10 enterprises have obtained approval for generic preparations at present. After the variety was included in the National Essential Medicine List in 2018, its clinical utilization rate has continued to rise. The terminal sales in public medical institutions exceeded RMB 200 million in 2024. After the coverage of centralized procurement, the price has stabilized. The supply of APIs is mainly dominated by domestic local enterprises, and the overall competitive landscape is relatively fragmented.

The original developer of flumazenil is Roche, with the original brand name Anexate®. The core compound patent expired in 1992. The main dosage form approved for the original product is injection, with conventional specifications of 5ml:0.5mg and 10ml:1.0mg. It has been included in the FDA Reference Listed Drug Catalog and China's *Catalog of Reference Preparations for Chemical Drugs*. In terms of domestic API registration, nearly 10 enterprises have completed CDE registration (status A) for flumazenil APIs at present. A number of domestic enterprises have obtained approval for the marketing of flumazenil injection, which can meet the supply demand for generic drug production. (Data as of June 2025, please refer to the official CDE website for the latest information)

CATO can provide a full set of flumazenil impurity reference standards. Most products are in stock. Orders for in-stock products placed before 16:00 will be shipped on the same day. All reference standards meet the requirements of multiple regulatory systems such as the Chinese Pharmacopoeia and FDA, with traceable quality parameters, which can fully support the impurity analysis needs in the process of API R&D, quality research and routine production.